Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
377
Employees377
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
377
Employees377

NTLA Key Statistics

Market cap
2.27B
Market cap2.27B
Price-Earnings ratio
-4.54
Price-Earnings ratio-4.54
Dividend yield
Dividend yield
Average volume
8.16M
Average volume8.16M
High today
$16.25
High today$16.25
Low today
$15.67
Low today$15.67
Open price
$15.76
Open price$15.76
Volume
261.91K
Volume261.91K
52 Week high
$28.25
52 Week high$28.25
52 Week low
$7.95
52 Week low$7.95

Stock Snapshot

The current Intellia Therapeutics(NTLA) stock price is $16.24, with a market capitalization of 2.27B. The stock trades at a price-to-earnings (P/E) ratio of -4.54.

As of 2026-06-26, Intellia Therapeutics(NTLA) stock has fluctuated between $15.67 and $16.25. The current price stands at $16.24, placing the stock +3.6% above today's low and -0.1% off the high.

The Intellia Therapeutics(NTLA)'s current trading volume is 261.91K, compared to an average daily volume of 8.16M.

In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $7.95.

In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $7.95.

NTLA News

Nasdaq 2d
Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.

Key Points Biotech companies offer investors the opportunity to place an early bet on game-changing treatments. This particular company just proved the streng...

Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.
Simply Wall St 3d
argenx And 2 Growth Stocks With Healthy Balance Sheets

Global growth is mixed, inflation signals are uneven and policy paths are still in focus, so it helps to focus on stocks where analysts already expect solid ear...

argenx And 2 Growth Stocks With Healthy Balance Sheets
Simply Wall St 5d
Intellia Therapeutics Is Up 29.4% After New Phase 3 Lonvo-z Data and FDA Filing - simplywall.st

...

Intellia Therapeutics Is Up 29.4% After New Phase 3 Lonvo-z Data and FDA Filing - simplywall.st

Analyst ratings

50%

of 22 ratings
Buy
50%
Hold
40.9%
Sell
9.1%

More NTLA News

Simply Wall St 7d
Intellia Therapeutics Stock Could Be 41.2% Undervalued After Phase 3 HAE Data

Intellia Therapeutics (NTLA) is back in focus after releasing detailed Phase 3 HAELO trial data for its CRISPR-based therapy lonvo-z in hereditary angioedema, a...

Intellia Therapeutics Stock Could Be 41.2% Undervalued After Phase 3 HAE Data

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.